Researchers from the University of North Carolina at Chapel Hill and Yale University have been awarded almost $10 million to study the many ways cocaine use during pregnancy can negatively affect interactions between mothers and their infants. The project’s researchers hope their findings will aid the development of new intervention strategies for helping both mothers and children, and prove valuable to others working in fields such as drug abuse and developmental disorders.

continue reading.....

Seattle’s Favorite Gourmet Cookies and Dessert Co. is recalling Orange Cranberry and Banana Nut Muffin Tops because they contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life threatening allergic reaction if they consume these products.

continue reading.....

PREMARIN® (conjugated estrogens) Vaginal Cream 0.5 g has been approved by the U.S. Food and Drug Administration (FDA) for a new indication and a new less frequent twice-weekly dosing regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

continue reading.....

New clinical data presented show first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in patients with high blood pressure aged 65 and over, compared to the angiotensin-converting enzyme (ACE) inhibitor ramipril[1].

continue reading.....

The FDA announced its update on the safety review of bisphosphonates, including FOSAMAX®, that found no clear association between overall bisphosphonate exposure and the rate of serious or non serious atrial fibrillation. Increasing dose or duration of bisphosphonate therapy was also not associated with an increased rate of atrial fibrillation. These findings are based on the Agency’s review of data from clinical studies of bisphosphonates.

continue reading.....

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced that the New Drug Application (NDA) for Solzira™ (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) has been withdrawn. The United States Food and Drug Administration (FDA) has requested that the data in a single study be reformatted.

continue reading.....

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on eye disease, vascular disease and cancer, announces promising six month follow-up results from its Phase IIb MIVI III trial, which was designed to evaluate the safety and efficacy of microplasmin in vitrectomy. The results were presented at the American Academy of Ophthalmology in Atlanta, USA, by Dr.

continue reading.....

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of proprietary drug delivery systems, presented the results of its exploratory study entitled “Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs” at the Diabetes Technology Society’s Conference in Bethesda, Maryland.

continue reading.....